Literature DB >> 6093438

Radiation therapy for brain metastases from malignant melanoma.

I C Stridsklev, S Hagen, O Klepp.   

Abstract

Thirty-nine patients who completed whole-brain irradiation treatment for brain metastases from malignant melanoma were analyzed. Median survival was 2 months, mean survival 4 months. Only 3 patients survived for 1 year, the longest survival being 19 months after irradiation. Twenty-one (53.8%) showed marked clinical improvement and 6 (40%) of the 15 evaluable patients had some objective regression of the brain metastases. A treatment of 7 fractions of 4.8 Gy in 9 to 14 days and concomitant chemotherapy with dacarbazine and lomustine in 16 patients was well tolerated. This seems to be a beneficial treatment for patients with a comparatively small intracranial tumour burden.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6093438     DOI: 10.3109/02841868409136017

Source DB:  PubMed          Journal:  Acta Radiol Oncol        ISSN: 0349-652X


  3 in total

1.  Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma.

Authors:  C Jacquillat; D Khayat; P Banzet; M Weil; M F Avril; P Fumoleau; M Namer; J Bonneterre; P Kerbrat; J J Bonerandi
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

2.  Radiation therapy for melanoma brain metastases: a systematic review.

Authors:  John F Thompson; Gabrielle J Williams; Angela M Hong
Journal:  Radiol Oncol       Date:  2022-08-14       Impact factor: 4.214

3.  Cerebral metastases from malignant melanoma: current treatment strategies, advances in novel therapeutics and future directions.

Authors:  Timothy L Siu; Suyun Huang
Journal:  Cancers (Basel)       Date:  2010-04-06       Impact factor: 6.639

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.